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Bunyaviruses pose a significant threat to human health, prosperity and 27 
food security. In response to viral infections, interferons (IFNs) upregulate the 28 
expression of hundreds of interferon stimulated genes (ISGs) whose 29 
cumulative action can potently inhibit the replication of bunyaviruses. We used 30 
a flow cytometry-based method to screen the ability of ~500 unique ISGs from 31 
humans and rhesus macaques to inhibit the replication of Bunyamwera 32 
orthobunyavirus (BUNV), the prototype of both the Peribunyaviridae family 33 
and Bunyavirales order. Candidates possessing antibunyaviral activity were 34 
further examined using a panel of divergent bunyaviruses. Interestingly, one 35 
candidate, ISG20, exhibited potent antibunyaviral activity against most viruses 36 
examined from the Peribunyaviridae, Hantaviridae and Nairoviridae families, 37 
whereas phleboviruses (Phenuiviridae) largely escaped inhibition. Similar to 38 
other viruses known to be targeted by ISG20, the antibunyaviral activity of 39 
ISG20 is dependent upon its functional ribonuclease activity. Through use of 40 
an infectious VLP assay (based on the BUNV minigenome system), we 41 
confirmed that gene expression from all 3 viral segments is strongly inhibited 42 
by ISG20. Using in vitro evolution, we generated a substantially ISG20-43 
resistant BUNV and mapped the determinants of ISG20 sensitivity/resistance. 44 
Taken together, we report that ISG20 is a broad and potent antibunyaviral 45 
factor yet some bunyaviruses are remarkably ISG20 resistant. Thus, ISG20 46 
sensitivity/resistance could influence the pathogenesis of bunyaviruses, many 47 














There are hundreds of bunyaviruses and many cause life-threatening 51 
acute diseases in humans and livestock. The interferon (IFN) system is a key 52 
component of innate immunity and type I IFNs limit bunyaviral propagation 53 
both in vitro and in vivo. Type I IFN signalling results in the upregulation of 54 
hundreds of IFN stimulated genes (ISGs) whose concerted action generates 55 
an ‘antiviral state’. Although IFNs are critical in limiting bunyaviral replication 56 
and pathogenesis, much is still unknown about which ISGs inhibit 57 
bunyaviruses. Using ISG expression screening, we examined the ability of 58 
~500 unique ISGs to inhibit Bunyamwera orthobunyavirus (BUNV), the 59 
prototypical bunyavirus. Using this approach we identified ISG20, an 60 
interferon stimulated exonuclease, as a potent inhibitor of BUNV. Interestingly 61 
ISG20 possesses highly selective antibunyaviral activity and multiple 62 
bunyaviruses are potently inhibited whilst some largely escape inhibition. We 63 
speculate that the ability of some bunyaviruses to escape ISG20 could 64 
influence their pathogenesis. 65 
 66 
INTRODUCTION 67 
There are over 350 known viruses in the Bunyavirales order 68 
(collectively known as bunyaviruses) that have recently been reclassified into 69 
nine families: Feraviridae, Fimoviridae, Hantaviridae, Jonviridae, Nairoviridae, 70 
Peribunyaviridae, Phasmaviridae, Phenuiviridae and Tospoviridae (1). Most 71 
bunyaviruses are carried and transmitted by arthropods such as mosquitoes, 72 
ticks, sand flies, or thrips, except the hantaviruses (Hantaviridae), which are 73 
typically transmitted via infectious aerosols usually originating from rodent 74 
excreta (2). Several bunyaviruses can cause severe human diseases, such as 75 
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La Crosse (LACV) and Oropouche (OROV) orthobunyaviruses 76 
(Peribunyaviridae family), Hantaan (HTNV) and Sin Nombre 77 
orthohantaviruses (Hantavirus family), severe fever with thrombocytopenia 78 
syndrome (SFTSV) and Rift Valley fever (RVFV) phleboviruses (Phenuiviridae 79 
family) and Crimean-Congo hemorrhagic fever orthonairovirus (CCHFV, 80 
Nairoviridae family) (2). Importantly, bunyaviral emergence and re-emergence 81 
represent continuous threats to global health and prosperity and bunyaviruses 82 
might have higher zoonotic potential than many other viruses (3). 83 
Bunyamwera orthobunyavirus (BUNV), the prototype virus of the 84 
Peribunyaviridae family and Bunyavirales order, remains an important 85 
research model for many significant bunyaviral pathogens. 86 
Like most viruses in the Peribunyaviridae family, BUNV possesses a 87 
tripartite negative-sense RNA genome comprised of large (L), medium (M) 88 
and small (S) genome segments. The S segment encodes the nucleocapsid 89 
(N) protein and the nonstructural protein NSs in overlapping reading frames. 90 
The M segment encodes a viral glycoprotein precursor (in the order Gn-NSm-91 
Gc). Whereas the L segment encodes the RNA-dependent RNA polymerase 92 
(2). The glycoprotein precursor is proteolytically cleaved into two mature viral 93 
membrane glycoproteins Gn and Gc and a non-structural protein NSm by host 94 
signal peptide and signal peptide peptidase (4). Bunyaviruses replicate in the 95 
cytosol and assemble and bud at membranes of the Golgi complex (2). During 96 
genome replication, each genome segment serves as an RNA-dependent 97 
RNA polymerase template for the generation of positive sense mRNA and 98 
antigenomic RNA (cRNA). The cRNA subsequently acts as a template for the 99 
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generation of nascent genomic RNA (gRNA). Thus, bunyavirus replication 100 
involves at least nine distinct RNA species (2).  101 
Following infection, bunyaviruses are sensed by the host. For example, 102 
the RNA genomes of orthobunyaviruses and phleboviruses carry uncapped 5’ 103 
triphosphate (5'-pppRNA) ends and short dsRNA structures, which can be 104 
sensed by the cytoplasmic RNA helicase, RIG-I (retinoic acid-inducible gene 105 
I) (5-7). Pattern recognition frequently results in the secretion of type I IFNs, 106 
which modulate multiple immune processes and place cells in an ‘antiviral 107 
state’, impeding the infection and replication of viruses (8). IFNs are known to 108 
inhibit bunyaviruses both in vitro and in vivo (9-16). Indeed, IFNs likely play a 109 
key role in constraining bunyavirus replication and pathogenesis as many 110 
short-lived asymptomatic infections can become severely pathogenic when 111 
the IFN defences of the host are compromised (17-22). Moreover, the 112 
importance of host IFN responses in combatting bunyaviral infection is 113 
underscored by the multitude of strategies that bunyaviruses employ to 114 
counteract host IFN responses. The NSs proteins of many bunyaviruses can 115 
be major virulence factors and act as potent IFN antagonists (23-25). These 116 
divergent NSs proteins utilise multiple strategies to inhibit host IFN responses 117 
(25, 26) including suppressing host mRNA transcription (25, 27, 28), blocking 118 
pattern recognition (11, 29, 30) or even disrupting type I IFN signalling by 119 
sequestering STAT1 and STAT2 into inclusion bodies (31).  120 
 Although bunyaviruses are potently inhibited by IFNs in vitro and this 121 
inhibition likely helps define bunyaviral pathogenesis, only a handful of ISGs 122 
have so far been ascribed antibunyaviral activity (32-36). In this study, using a 123 
flow cytometry-based gain of function screening assay, we considered the 124 
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ability of 488 unique human and macaque ISGs to inhibit the prototypical 125 
bunyavirus (BUNV). Here we show that the antiviral exonuclease ISG20 (37) 126 
has broad spectrum antiviral activity against multiple bunyaviruses. Similar to 127 
the known targets of ISG20, the antiviral effect is dependent upon functional 128 
exonuclease activity (37-41). Using in vitro evolution, we selected an ISG20 129 
resistant BUNV and show that viral resistance maps to multiple genome 130 
segments. Importantly, even low levels of endogenous ISG20 expression 131 
potently inhibited BUNV whereas some bunyaviruses effectively escaped 132 
inhibition by ISG20. These data suggest that ISG20 could play a key role in 133 
the host response to bunyaviral infection and sensitivity/resistance to this 134 
factor might therefore influence bunyaviral pathogenesis. 135 
 136 
RESULTS 137 
BUNV-eGFP completes a single round of infection in MT4 cells. We 138 
previously reported a ‘multicycle’ screen searching for host factors capable of 139 
attenuating BUNV replication. Under these conditions, IFITM3 and IRF1 were 140 
identified as modest inhibitors of BUNV replication (42). Because BUNV is 141 
highly sensitive to inhibition by type I IFN in vitro, we hypothesized that 142 
additional ISGs with anti-BUNV activity likely exist. We recently expanded our 143 
ISG library to include ~350 additional ISGs from rhesus macaques (43), 144 
increasing our total library size to 488 unique ISGs (~25% more genes). This 145 
enthused us to search again for interferon induced effectors that inhibit BUNV. 146 
In order to use arrayed ISG expression screening (42-45) to identify ISGs with 147 
anti-BUNV activity, we needed to select a cell line that could be easily 148 
transduced with ISG-encoding lentiviral vectors and be susceptible to 149 
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subsequent infection with BUNV. We have previously used human MT4 T 150 
cells for this screening approach (43, 44), so we examined whether these 151 
cells were susceptible to BUNV infection. We utilised recombinant BUNV-152 
eGFP, in which GFP is fused with the N-terminus of a truncated Gc 153 
glycoprotein (46), as this reporter virus could easily be used for flow cytometry 154 
based screening assays. Interestingly, although MT4 cells could be readily 155 
infected with BUNV-eGFP (Fig. 1A and B), this virus appeared to be unable to 156 
spread throughout the culture and the percentage of infected cells decreased 157 
over time (Fig. 1C). The lack of propagation in MT4 cells appeared to be 158 
specific to the recombinant GFP-tagged virus as wt BUNV replicated 159 
efficiently (reaching titers of over 106 PFU/ml at 48 h.p.i), whereas no plaque 160 
forming units were produced from the equivalent multiplicity of BUNV-eGFP 161 
(Fig. 1D and E). The exact mechanism that prevented BUNV-eGFP 162 
propagation in MT4 cells is unknown, however the formation of abundant 163 
virus-like GFP puncta (Fig. 1A) suggested BUNV-eGFP could efficiently 164 
express multiple viral genes and complete much of the viral lifecycle in these 165 
cells. Construction of BUNV-eGFP required deleting 350 residues from the N-166 
terminus of Gc to accommodate the GFP moiety. It is therefore possible that 167 
the N-terminus of Gc is essential for the efficient generation of BUNV 168 
infectious progeny from MT4 cells but is dispensable in other contexts (46, 169 
47).  170 
 171 
ISG expression screening reveals candidate genes with anti-BUNV 172 
activity. The unanticipated single round of infection of BUNV-eGFP in MT4 173 
cells enabled us to conduct a screen searching for ISGs that inhibit the early 174 
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stages of the BUNV lifecycle (after viral gene expression but before the 175 
genesis of infectious progeny). Arrayed ISG-expression screening involves 176 
exogenously expressing ISGs within target cells that are susceptible to 177 
infection by the virus of interest (43-45). Under screening conditions, not all 178 
the cells in a well will express the ISG. Viruses can therefore efficiently 179 
replicate in the ISG-negative cells and abundant progeny virus can overwhelm 180 
a protective ISG in adjacent cells. Thus, ‘multicycle’ ISG expression screens 181 
can potentially underestimate the protective effect of some ISGs and limiting 182 
the virus to a single round of infection could improve the identification of 183 
candidate antiviral factors. Thus, we took advantage of the late defect in 184 
BUNV-eGFP replication in MT4 cells to examine the ability of 488 different 185 
ISGs to inhibit a single round of BUNV infection (Fig. 2A-D). We considered 186 
ISGs from H. sapiens and M. mulatta (43) as both primate species likely 187 
support BUNV infection (48, 49). The protective effect of each ISG was 188 
quantified using two-colour flow cytometry (Fig. 2C) and the level of infection 189 
in the presence of each ISG is plotted as the percentage of the screen 190 
average (Fig. 2D). 191 
Multiple ISGs conferred considerable protection from BUNV infection in 192 
the initial screen (Fig. 2D). Many of the candidate anti-BUNV ISGs were 193 
known restriction factors (such as ISG20, IFITM3 and Mx1). In addition, 194 
multiple ISGs (such as IRF1 and IRF7) likely conferred protection by 195 
engendering a polygenic antiviral state by stimulating IFN expression or ISRE 196 
(interferon stimulated response element) driven transcription (43). 197 
 To validate the screening results, independent lentiviral vector 198 
preparations were used to consider the ability of the 20 most protective 199 
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human and macaque candidate antiviral ISGs to protect MT4 cells from 200 
titrated BUNV-eGFP challenge (Fig. 2E). This confirmed the ability of the 201 
exogenously expressed ISGs to confer protection from BUNV infection. 9 202 
human ISGs and 5 macaque ISGs, which conferred  5-fold protection were 203 
selected for further investigation (Fig. 2E and Tables 1 and 2). 204 
 205 
ISG20 has specific antibunyaviral activity. Many divergent viruses are 206 
classed as bunyaviruses (1, 2). To further investigate the antiviral spectrum of 207 
the selected ISGs against bunyaviruses, we screened the ability of each ISG, 208 
which conferred 5-fold protection from BUNV, to inhibit a panel of 15 209 
divergent bunyaviruses (including members of four distinct families). Our 210 
panel included viruses that can cause serious clinical infections, such as 211 
Heartland phlebovirus (HRTV) and SFTSV as well as agricultural pathogens 212 
such as Schmallenberg orthobunyavirus (SBV). To compare these divergent 213 
viruses we used Vero cells, which support the efficient propagation of many 214 
divergent viruses due in part to their defective IFNB1 gene (50). To ensure 215 
stable phenotypes, we established Vero cell clones that were transduced with 216 
vectors encoding human EHD4, HK2, IFITM3, IRF1, ISG20, NOS2A or SCO2 217 
in addition to clones modified to express macaque ISG20, LGALS9 or RHOB. 218 
Single cell clones were selected that had similar BUNV inhibitory profiles to 219 
the parental ‘bulk’ population they were derived from. We were unable to 220 
establish stable cell lines expressing IDO1, BCL3 or PFKFB3. The broad 221 
spectrum antiviral activity of IDO1, through tryptophan depletion, is well 222 
documented (43) and persistent tryptophan depletion likely inhibited the 223 
generation of single cell clones. We reasoned that the ability of BCL3 and 224 
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PFKFB3 to perturb normal Vero cell physiology (preventing the generation of 225 
stable lines) made it less likely that these ISGs possessed direct anti-BUNV 226 
activity and more likely that the global cellular effect of overexpressing these 227 
genes reduced BUNV infectivity. Thus, we did not consider IDO1, BCL3 or 228 
PFKFB3 further. We confirmed the expression of eight ISGs using western 229 
blotting (Fig. 3A). However, we were unable to establish western blotting 230 
conditions that detected NOS2A or RHOB.  We also assessed the 231 
transduction and clonality of each cell line by monitoring RFP expression from 232 
the lentiviral vector (Fig. 3B). We then conducted a ‘mini screen’ of the ten 233 
remaining ISGs (7 human and 3 macaque ISGs) and assessed the virus yield, 234 
of our panel of bunyaviruses, in the presence of each ISG (Fig. 3C). Because 235 
one clone of each ISG was investigated, we used this ‘mini screen’ approach 236 
to select candidates for subsequent examination and the ‘mini screen’ does 237 
not constitute a precise survey of ISGs that inhibit representative 238 
bunyaviruses. Moreover, NOS2A caused little inhibition of any of our panel of 239 
viruses. Without further investigation, it is impossible to discern whether 240 
NOS2A was poorly expressed or has limited antibunyaviral activity. 241 
Nonetheless, some patterns emerged and the inhibitory effect of each ISG on 242 
our panel of bunyaviruses is summarized in a heatmap (Fig. 3D). 243 
As observed in previous studies, exogenous IRF1 expression initiated 244 
a gene expression programme (43) that led to the inhibition of most 245 
bunyaviruses. IFITM3, a well-characterised restriction factor that inhibits the 246 
fusion of cellular and viral membranes (51) appeared to have broad spectrum 247 
antibunyaviral activity. IFITM3 reduced the infectious yield and/or the plaque 248 
area of most of our panel of bunyaviruses. The magnitude of protection was 249 
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variable as IFITM3 potently inhibited several viruses (such as Kairi 250 
orthobunyavirus (KRIV), SBV, Dugbe orthonairovirus (DUGV) and HRTV), 251 
whereas other viruses were only weakly inhibited or not inhibited at all (such 252 
as OROV and Puumala orthohantavirus (PUUV)). IFITM3 has previously been 253 
described to inhibit multiple bunyaviruses (36, 52). Exogenous EHD4 also 254 
potently inhibited multiple bunyaviruses (including SBV, Batama 255 
orthobunyavirus (BMAV) and PUUV) while some viruses were unaffected. 256 
Whether this inhibition could be physiologically relevant is questionable as 257 
EHD4 is usually expressed at low levels and is only weakly stimulated by 258 
IFNs (53, 54). Exogenous HK2 and RHOB caused substantial inhibition in 259 
some settings and potently inhibited BUNV and SBV respectively. However, 260 
HK2 and RHOB typically caused only modest inhibition of our panel of 261 
viruses. 262 
In contrast to the other ISGs, human and macaque ISG20 potently 263 
inhibited the majority of our panel of bunyaviruses (Fig. 3E), in some cases 264 
reducing the virus yield by more than 1000-fold (PUUV and KRIV). 265 
Intriguingly, whilst most bunyaviruses were susceptible to ISG20, Anopheles 266 
A orthobunyavirus (ANAV), Capim orthobunyavirus (CAPV) and the three 267 
tested phleboviruses (phenuiviridae family) were largely resistant. ISG20 is an 268 
important antiviral exonuclease (37) that has maintained robust interferon 269 
stimulation for hundreds of millions of years (54) and has possibly played a 270 
key antiviral role throughout this time with antiviral activity being documented 271 
against multiple viruses (37-41). Hitherto, ISG20 has not been ascribed 272 
antibunyaviral activity and the observation that the potent antiviral activity is 273 
evaded by multiple viruses suggests ISG20 directly inhibits specific 274 
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bunyaviruses (as opposed to inducing global cellular effects). We therefore 275 
focussed our attention on this ISG. 276 
 277 
Exonuclease activity underpins ISG20-mediated antibunyaviral activity. 278 
Multiple viruses have previously been shown to be sensitive to ISG20, with 279 
the majority of inhibition being dependent on ISG20’s 3 to 5 exonuclease 280 
activity (37-41). A single substitution (D94G), part of the DEDDh motif in 281 
ISG20’s active site (55), can abrogate exonuclease activity and ablate the 282 
inhibition of a number of viruses (37-41, 56). To investigate whether 283 
exonuclease activity is essential for anti-BUNV activity, we generated cell 284 
lines that expressed catalytically inactive forms of human and macaque 285 
ISG20 (D94G). While the expression of human and macaque orthologs both 286 
reduced the infectious yield of BUNV (by ~100 fold and ~10 fold respectively) 287 
and substantially reduced the area of individual BUNV plaques, the 288 
catalytically defective mutants had no detectable antiviral activity even though 289 
they were expressed at similar levels (Fig. 4B-E). 290 
 Our screen of a panel of bunyaviruses indicated that human ISG20 291 
might generally possess more potent antibunyaviral activity than the macaque 292 
ortholog (Fig. 3 and Fig. 4A-E) even though they are 98% identical (at the 293 
amino acid level), differing at just 4 amino acid positions (Fig. 4A). Intriguingly, 294 
macaque ISG20 also appeared to be more active against Capim 295 
orthobunyavirus (CAPV) (Fig. 3C) suggesting ISG20 orthologs might possess 296 
divergent antibunyaviral specificities. As western blot analysis revealed 297 
greater expression levels of ISG20 in our human clone (Fig. 3A and Fig. 4E), 298 
we examined ‘bulk populations’ of Vero cells, transduced in parallel with 299 
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human and macaque ISG20, and found that these ‘bulk populations’ 300 
appeared to express equivalent levels of ISG20 (Fig. 4F). Importantly, in this 301 
context human and macaque ISG20 inhibited BUNV to similar degrees (Fig. 302 
4G).  Crucially, the highly specific antibunyaviral activity of ISG20 was also 303 
evident in these ‘bulk populations’ as parallel infections with single cycle 304 
RVFV (strain 35/74) (57) were completely unaffected by ISG20 (Fig. 4G). We 305 
therefore speculate that any observed species-specific variation in ISG20 306 
activity (Fig. 3C) is perhaps due to different ISG20 expression levels and 307 
clonal variation.  However, we cannot exclude the possibility that primate 308 
ISG20 orthologs could possess divergent antibunyaviral specificities.  309 
 310 
Gene expression from all BUNV genome segments is inhibited by ISG20. 311 
BUNV possesses a tripartite single stranded negative sense RNA genome (L, 312 
M and S segments). To investigate whether ISG20 targets a specific genome 313 
segment or all three segments, we assessed the inhibitory effect of ISG20 on 314 
VLP-based reporter gene expression. In this assay, infectious VLPs (iVLPs) 315 
were utilized that contained a single BUNV minigenome derived from just one 316 
of the three segments. The iVLPs were assembled in BSRT7/5 cells by 317 
supplying all the essential viral proteins in trans (L protein; Gn and Gc viral 318 
glycoproteins; and N protein) together with, a single minigenome transcription 319 
vector (either pT7riboBUNLRen(-), -MRen(-) or -SRen(-)) representing each 320 
genome segment. The minigenomes contained the full length 5’- and 3’- 321 
UTRs of BUNV, with Renilla luciferase inserted in place of the viral ORF in 322 
each segment. The iVLPs were used to infect Vero cells expressing either wt 323 
ISG20 or ISG20D94G. Interestingly, all three minigenome segments were 324 
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targeted and luciferase expression from L, M and S segments was 325 
substantially reduced by ISG20 (Fig. 5A). This ~5 to 10-fold reduction was 326 
entirely dependent on functional exonuclease activity as the D94G catalytic 327 
mutant caused no inhibition of reporter gene expression (Fig. 5A). 328 
 We next considered which RNA species might be targeted by ISG20 as 329 
multiple RNA forms derived from each genome segment are required for the 330 
bunyaviral lifecycle. Thus, viral genomic RNA (gRNA), antigenomic RNA 331 
(cRNA) and messenger RNA (mRNA) species could all conceivably be targets 332 
of ISG20. We were not aware of existing bunyaviral strand-specific qPCR 333 
assays so based on published norovirus and influenza A virus strategies (58, 334 
59), we developed a tagged taqman qRT-PCR assay that efficiently detects 335 
the desired S-segment RNA species but poorly amplifies 336 
undesired/nonspecific targets. The exception was mRNA whose entire 337 
sequence is also present in the cRNA species except for the ‘cap-snatched’, 338 
host cell derived, 5’ end (Fig. 5C). In this instance, we estimated the mRNA 339 
copy number by subtracting the cRNA copy number from the value obtained 340 
from the mRNA assay (which detects all positive sense viral RNAs). 341 
Validation of the assay specificity is shown in Figure 5D. Since a single 342 
infectious cycle of BUNV in Vero cells is approximately 6 hours (46), we 343 
examined the S-segment at 0h, 2h, 4h and 6h post infection. Using this 344 
approach, all three S-segment RNAs appeared to be substantially diminished 345 
(~10-fold) by ISG20 following infection of Vero cells (Fig. 5E).  However, we 346 
are unable to discern whether this reduction is due to the S-segment RNAs 347 
being degraded by ISG20 or is an indirect consequence of ISG20 inhibiting 348 
some other facet(s) of the BUNV lifecycle.   349 
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Mapping the viral determinants of ISG20 antiviral activity. In vitro 351 
evolution/serial passaging has often been employed to study the antiviral 352 
mechanism of many antiviral factors and frequently reveals the sensitivity 353 
determinants that represent a molecular interface between host and pathogen 354 
(60-64). To investigate whether BUNV can access sequence space that 355 
confers resistance to ISG20, we passaged BUNV in Vero cells expressing 356 
human ISG20 (or modified using an ‘empty’ vector). We periodically 357 
monitored the ability of the passaged swarm to plaque/replicate in the 358 
presence of ISG20. Following 20 passages, partial ISG20 resistance was 359 
observed and after 40 passages in the presence of ISG20, we were able to 360 
isolate a viral swarm that replicated far more efficiently in the presence of 361 
ISG20, forming larger plaques and yielding more infectious particles (Fig. 6A-362 
C). This P40 virus replicated substantially faster than the parental virus, in the 363 
presence of ISG20, yielding ~100-fold more virus at 48 h.p.i (Fig. 6C). 364 
Crucially, the P40 virus was weakly attenuated on naïve Vero cells suggesting 365 
that the ISG20 resistance was not merely due to adaptation to Vero cells 366 
during the passage series (Fig. 6C). 367 
 To investigate the viral determinants that rendered BUNV resistant to 368 
ISG20, we sequenced the L, M and S segments of the P20 and P40 swarms 369 
using direct sequencing of RT-PCR products. The sequences of the termini 370 
were also simultaneously determined using 3'-RACE. Sequence analysis 371 
revealed mutations in all three segments at P20 and P40, some of which were 372 
transient polymorphisms.  By P20, apart from a reversion to the GenBank 373 
sequence (M segment A3568G) only a single mutation was selected to near 374 
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uniformity in the presence of ISG20 (Table 3). This S segment mutation 375 
(A330C) encodes changes in N (N82T) and NSs proteins (T76P) and is 376 
possibly the major determinant of the ISG20 resistance observed at P20. 377 
Sequencing of the P40 swarm revealed multiple mutations in all genome 378 
segments that had been selected to near uniformity (Table 3). Importantly, 379 
none of these mutations were found in the P40 Vero-EMPTY passaged virus 380 
(Table 4).   381 
To assess the significance of these mutations we generated 382 
reassortant viruses, using reverse genetics, that contained parental and P40 383 
mutant genome segments (a prime (') denotes the mutant segment(s) used).  384 
Importantly, a virus rescued from all three P40 genome segments (designated 385 
rBUN-L'M'S') recapitulated the phenotype of the P40 swarm and replicated 386 
more efficiently than the wt virus in the presence of ISG20 (Fig. 6D). In 387 
accordance with the observation that ISG20 inhibits gene expression from all 388 
three genome segments (Fig. 5A), the addition of a single P40 genome 389 
segment was not sufficient to confer equivalent ISG20 resistance to the L'M'S' 390 
virus (Fig. 6D).  Moreover, the contribution of each individual mutant segment 391 
to ISG20 resistance appeared unequal with S' and M' conferring more 392 
substantial resistance than L'. Thus, ISG20 resistance appears to be 393 
multipartite and mutations are required on more than one genome segment 394 
for the P40 virus to resist ISG20.  Because the mutant S' segment contained 395 
two substitutions in NSs (S3L and T76P), we wondered whether the mutant 396 
NSs still functioned as an interferon antagonist.  Interestingly, mutant NSs 397 
appeared to have reduced activity as an IFN antagonist in an EMCV inhibition 398 
assay (Fig. 6E). 399 
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  400 
Endogenous ISG20 has anti-BUNV activity. A recurrent obstacle in 401 
understanding how the IFN induced ‘antiviral state’ inhibits a virus is that 402 
viruses are often simultaneously inhibited by multiple IFN induced defences. 403 
In this scenario, loss of function experiments can be challenging as viral 404 
replication might not be substantially rescued by removing a single ISG 405 
(because multiple inhibitory effectors might still be fully active). Thus, we 406 
searched for cell lines that expressed readily detectable ISG20 without the 407 
need for prior stimulation. HeLa cells are known to express ISG20 in the 408 
absence of IFN treatment (37, 38) (Fig. 6F). Accordingly, the ISG20 resistant 409 
swarm grew far more efficiently than the parental virus in unmodified HeLa 410 
cells with the P40 virus yielding ~100-fold more virus at 24 hours post 411 
infection (Fig. 6G). However, the control P40 virus (Vero-EMPTY) didn’t 412 
exhibit any growth advantage on unmodified HeLa cells (Fig. 6G green line). 413 
Crucially, this difference between the P40 ISG20 resistant virus and the 414 
parental virus was largely due to endogenous ISG20 as shRNA knockdown of 415 
ISG20 increased the replication of the parental virus so that it replicated with 416 
similar kinetics to the P40 virus (Fig. 6H). Thus, even low levels of 417 
endogenous ISG20 can cause substantial inhibition of BUNV, suggesting that 418 
IFN-induced upregulation of ISG20 (Fig. 6F) likely represents a formidable 419 
block to the replication of BUNV and other sensitive bunyaviruses. 420 
 421 
DISCUSSION 422 
Interferons rapidly engender an ‘antiviral state’ in host cells through the 423 
induction and expression of hundreds of ISGs, many of which have antiviral 424 
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functions. It is well documented that interferons can suppress the replication 425 
of divergent bunyaviruses both in vitro and in vivo (9-15). In this study, we 426 
screened 488 ISGs and identified multiple ISGs that inhibited the prototypical 427 
bunyavirus (BUNV). We reveal that ISG20 exhibits potent and highly specific 428 
antibunyaviral activity. ISG20 is robustly upregulated in response to 429 
interferons, and the ISG20 promoter contains ISRE and GAS elements that 430 
respond to type I, type II and type III interferons (38, 65). Multiple studies have 431 
highlighted the importance of ISG20 as an antiviral effector that targets 432 
multiple viruses (37-41), and several bunyaviruses can be added to the 433 
growing list of ISG20 targets. Thus, ISG20-mediated inhibition could constrain 434 
bunyaviral replication as part of an interferon response and this targeted 435 
activity of ISG20 could limit the pathogenesis of specific bunyaviruses.  436 
We previously screened the ability of over 350 human ISGs to inhibit 437 
BUNV in Huh7 cells and did not identify any candidates that inhibited BUNV 438 
more than 2-fold (42). Nonetheless, the most inhibitory ISGs (IFITM3 and 439 
IRF1) were re-identified in this study. Crucially, ISG20 has been reported to 440 
lack specific antiviral activity in Huh7 cells (41), potentially explaining why 441 
ISG20 was not ascribed antibunyaviral activity in previous screens. Moreover, 442 
the unanticipated single round of BUNV-eGFP infection in MT4 cells likely 443 
increased the fidelity of the primary screen, facilitating the identification of 444 
multiple candidate effectors in this study. 445 
A handful of ISGs previously reported to inhibit BUNV (PKR, IFI44 and 446 
Viperin (32)) were not re-identified in our primary screen. Notably, we are 447 
unable to achieve efficient transduction with PKR-encoding SCRPSY vectors 448 
(43), possibly explaining the lack of antiviral activity in this primary screen. 449 
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Akin to ISG20 in Huh7 cells, multiple ISGs possess cell-type dependent 450 
activity. Accordingly, parallel screens in different cell lines can identify 451 
different antiviral candidates (43). Thus, the anti-BUNV activity of IFI44 and 452 
Viperin could be context dependent or might simply block the virus lifecycle 453 
after efficient GFP expression was achieved (further work would be necessary 454 
to explore either possibility). 455 
The antiviral activity of ISG20 appeared to rely on its 3' to 5' 456 
exoribonuclease function as a single amino acid substitution within the active 457 
site (D94G) abrogated antiviral activity. However, it is possible that disrupting 458 
this coordinating residue could grossly alter the structure of ISG20, placing a 459 
slight caveat over this interpretation. In contrast to RNase L, an interferon 460 
stimulated ribonuclease that indiscriminately cleaves single-stranded RNA 461 
following UU and UA motifs, ISG20 is able to discriminate between self RNAs 462 
(ribosomal RNAs (38, 39) and -actin mRNA (40)) and nonself (viral) RNAs. 463 
Similarly, we observed that Vero cells expressing exogenous ISG20 appeared 464 
healthy (38) and that plasmid based expression was equally efficient in Vero-465 
ISG20 and control cell lines (unpublished observations). Nonetheless, it 466 
seems likely that host RNAs do not completely escape ISG20 as, in 467 
accordance with previous observations (56), Vero cells modified to express 468 
ISG20 proliferated more slowly than unmodified cells (unpublished 469 
observations). Importantly, the fact that all the phleboviruses we tested (RVFV 470 
strains MP12 and 35/74, SFTSV and to a lesser extent HRTV) and two 471 
orthobunyaviruses (CAPV and to a lesser extent ANAV) largely escaped 472 
ISG20-mediated inhibition, underscores the high level of target specificity 473 
exhibited by ISG20. Whether these resistant viruses actively antagonize 474 
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ISG20 function (by deploying viral countermeasures) or whether they evade 475 
inhibition through minimizing sequence/structural motifs targeted by ISG20 is 476 
worthy of future investigation.  We currently have no information on whether 477 
bunyaviral protein or RNA is predominantly involved and the precise viral 478 
sensitivity/resistance determinants that underlie ISG20’s selective 479 
antibunyaviral activity are completely unknown (and could have influence on 480 
the pathogenicity of bunyaviruses). 481 
Interestingly, although ISG20 is highly specific, all three luciferase-482 
encoding minigenomes (reminiscent of each BUNV genome segment) were 483 
targeted by ISG20. The VLP system we used can only complete a single 484 
round of infection yet was potently inhibited by ISG20. Thus, ISG20 can 485 
represent a rapid and effective block to the bunyavirus lifecycle. Crucially, 486 
viral replication and transcription in the VLP-infected cells were carried out by 487 
ribonucleoproteins (RNPs) packaged into the VLPs, in which only one 488 
minigenome species (representing a specific genome segment) was present. 489 
Therefore, efficient reporter gene expression is not dependent upon gene 490 
expression from other genome segments and, under these conditions, ISG20 491 
cannot mediate indirect inhibition by targeting another genome segment. 492 
Thus, it is likely that following VLP infection, ISG20 directly targeted L, M and 493 
S minigenome segments. One possible caveat is that the minigenome 494 
segments are considerably shorter than the wt segments and therefore might 495 
not fully recapitulate the ISG20 sensitivity/resistance of the complete 496 
segments.  Moreover, internal RNA structures can govern 497 
sensitivity/resistance to ISG20 inhibition (38) and we cannot rule out that the 498 
luciferase ORF constitutes a particularly attractive target for ISG20.  499 
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Because BUNV genome replication and gene expression are tightly 500 
coupled, it is unclear whether minigenome gRNA, cRNA, mRNA or a 501 
combination of these species is targeted by ISG20. Using qRT-PCR, we 502 
further examined the S segment RNA in the context of replication competent 503 
unmodified BUNV. The quantification of three S-segment RNAs (gRNA, 504 
cRNA, mRNA) indicated that the abundance of all three was decreased by 505 
ISG20. Considering the VLP data and these qPCR data together, it seems 506 
likely that S-segment RNAs are directly targeted by ISG20. However, we 507 
cannot exclude the possibility that the observed reduction in S-segment RNAs 508 
is an indirect consequence of reduced viral polymerase activity caused by 509 
ISG20 inhibiting another aspect of the BUNV lifecycle.  510 
Development of an ISG20-resistant BUNV through in vitro evolution 511 
revealed multiple viral determinants of ISG20 antiviral sensitivity/resistance. 512 
The mutations required for ISG20-resistance did not map to a single genome 513 
segment and instead changes were observed in all three segments. Although 514 
individual mutant segments could increase virus growth in the face of ISG20, 515 
no single mutant segment could recapitulate the considerable resistance 516 
observed using all three mutant segments. This polygenic resistance profile 517 
considered together with the sensitivity of all three minigenomes to ISG20-518 
mediated inhibition suggests that multiple BUNV RNA segments are likely 519 
targets of ISG20. We speculate that if all genome segments are targeted by 520 
ISG20, then mutations on each segment could plausibly make these viral 521 
RNAs less attractive substrates for ISG20.  Notably, excluding reversion to 522 
the GenBank sequence, the only M segment mutation selected in the 523 
presence of ISG20 was in a noncoding region (A4388G). This observation 524 
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could suggest that BUNV RNA sequence or structural elements might define 525 
sensitivity/resistance to ISG20.  However, we cannot exclude a role for viral 526 
proteins in conferring resistance to ISG20.  Notably, the S' segment conferred 527 
the most substantial resistance to ISG20 and by P20 a substitution in N 528 
protein (N82T) had been selected to near uniformity.  Because the N protein 529 
forms a complex with RNAs from all segments, it is possible that N protein 530 
might influence ISG20 sensitivity. However, in the only instance where we 531 
assessed protein function (derived from the ISG20 resistant virus), the mutant 532 
NSs protein appeared to be less potent as an interferon antagonist than the 533 
parental protein.  Although this is not evidence for RNA based ISG20 534 
resistance, it is concordant with this possibility. Put simply, the mechanistic 535 
basis of how the P40 virus (or any bunyavirus) resists ISG20 is unknown.  536 
Moreover, whilst progress has been made (38, 56), the molecular features 537 
that define RNAs as sensitive or resistant to ISG20-mediated inhibition 538 
(underlying self-nonself discrimination by ISG20) have yet to be fully 539 
elucidated.  540 
In summary, we reveal that ISG20 inhibits specific bunyaviruses and 541 
demonstrate that endogenous ISG20 can potently inhibit BUNV replication. 542 
Our study reinforces the notion that ISG screening is a powerful method for 543 
identifying antiviral effectors. Moreover, the molecular basis of how interferons 544 
constrain the replication of an important group of viral pathogens and how 545 
some viruses escape this inhibition could impact the pathogenesis of 546 
bunyaviruses of clinical significance, many of which cause life-threatening 547 













MATERIALS AND METHODS 550 
 551 
Cells and viruses. MT4 cells were maintained in RPMI 1640 (GIBCO) 552 
supplemented with 9% fetal bovine serum (FBS) and 100μg/ml Gentamicin. 553 
BHK-21 cells and BSRT7/5 cells (modified to stably express T7 RNA 554 
polymerase) (66), were grown in Glasgow minimum essential medium 555 
(GMEM, Thermo Fisher Scientific) supplemented with 9% newborn bovine 556 
serum (NBS) or FBS respectively in addition to 10% Tryptose Phosphate 557 
Broth. BSR-T7/5 cell medium was additionally supplemented with 1 mg/ml of 558 
Geneticin (G418) sulfate (Calbiochem). Vero-E6 (referred to as Vero 559 
throughout), HeLa, HEK 293T and A549 Npro cells (67) (expressing the 560 
bovine viral diarrhea virus NPro protein) were maintained in Dulbecco’s 561 
modified eagle medium (DMEM, Thermo Fisher Scientific) supplemented with 562 
9% FBS. HEK 293T cell medium was also supplemented with 100μg/ml 563 
Gentamicin. 564 
 15 bunyaviruses were used in the study including BUNV, Cache Valley 565 
virus (CVV), Kairi virus (KRIV), Anopheles A virus (ANAV), Tacaiuma virus 566 
(TCMV), Boraceia virus (BORV), Capim virus (CAPV), Oropouche virus 567 
(OROV), Schmallenberg virus (SBV), Batama virus (BMAV); Puumala virus 568 
(PUUV), RVFV (MP12), SFTSV, and Heartland virus (HRTV). The rBUN-Gc-569 
EGFP (or BUNV-eGFP) is a recombinant BUNV where the truncated Gc is 570 
tagged with EGFP (46). The single cycle RVFV system was described 571 













Plasmids. The SCRPSY lentiviral vector (Genbank accession number 574 
KT368137) and the human and macaque ISG libraries have been described 575 
previously (43-45). The shRNA-encoding lentiviral vector targeting ISG20 was 576 
generated by PCR using the human U6-promoter as a template and the 577 
following oligonucleotides 5’-578 
CTCTCTGAATTCCTGCAGAAGGTCGGGCAGGAAGAGGGCCTA-3’ and 5’- 579 
TCTCTCGAATTCAAAAAGGTGCTGTGCTGTACGACAAGTTCGAAAACTTA580 
TCGTACAGCACAGCACCGGTGTTTCGTCCTTTCCACAAGATATATAAAG -581 
3’. The PCR product was inserted, using EcoR1, into CSPW (68). The shRNA 582 
GFP has been described previously (68). Plasmids pTM1BUNL, pTM1BUNM 583 
and pTM1BUNN (encoding BUNV proteins L; M-polyprotein precursor; and 584 
N), and pT7riboBUNLRen(-), pT7riboBUNMRen(-) and pT7riboBUNSRen(-) 585 
for generating viral genomic-sense minigenomes, have been described 586 
previously (69). Full length cDNA sequences of L, M and S segments were 587 
subcloned into plasmid pTVT7R (0,0) (70) to generate three rescue plasmids 588 
pTVT7 BUNL(+), pTVT7 BUNM(+) and pTVT7 BUNS(+).  589 
 590 
FACS-based screening. The FACS-based screening assay was performed 591 
in a similar fashion to screens described previously (43-45). Briefly, two 592 
lentiviral vector-encoded ISG Libraries consisting of 488 unique ISGs 593 
including 394 human ISGs and 344 macaque ISGs (43) were used to 594 
transduce MT4 cells. The ISG was expressed from the completely spliced 595 
'early' HIV-1 mRNA, while TagRFP (a surrogate marker for transduction) was 596 
expressed from an unspliced late HIV-1 mRNA (43). This vector format was 597 
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previously validated ensuring that RFP-expressing cells were also ISG 598 
positive (using EGFP inserted in place of the ISG, unpublished observations).  599 
Target MT4 cells were transduced with lentiviral vectors encoding the human 600 
and macaque ISGs and incubated for 48 hours (to allow ISG expression) prior 601 
to challenge with BUNV-eGFP at an input equivalent to a multiplicity of 602 
infection (MOI) 5 (Fig 1C) determined using Vero cells. This dose resulted in 603 
an average of ~35% infection. At 48 hours postinfection (p.i), cells were 604 
collected and fixed with 4% formaldehyde. The percentage of transduced cells 605 
that were infected with BUNV-eGFP was determined by flow cytometry using 606 
a Guava EasyCyte flow cytometer (Millipore). 607 
 608 
Lentiviral vector production and transduction assays. Lentiviral stocks 609 
were generated in 293T cells by co-transfection of the SCRPSY lentiviral 610 
plasmid, a plasmid expressing the HIV-1 NL4-3 gag-pol (pNLGP) and a 611 
plasmid expressing the vesicular stomatitis virus glycoprotein (pVSV-G) in a 612 
ratio of 250ng:25ng:5ng in a 96-well plate (for ISG library production) or 613 
5μg:5μg:1μg in a 10cm dish (for confirmatory assays). The SCRPSY lentiviral 614 
plasmid encodes a puromycin-resistance gene in a single ORF together with 615 
TagRFP separated by a FMDV 2A ‘ribosomal skipping’ peptide 616 
(PAC2ATagRFP GenBank: ANN89731.1) that facilitated puromycin selection 617 
of transduced cells. Supernatants from 10cm dishes were collected at 48 h, 618 
72 h and 96h posttransfection, clarified by filtration through a 0.22μm filter and 619 
stored at -80. For transduction assays, MT4 or Vero cells were seeded in 620 
either 96-well (40000 cells/well) or 24-well plates (120000 cells/well). Vero 621 
cells were transduced with lentiviral vectors by spinoculation at 1600 rpm for 622 
 o
n









1h. For confirmatory experiments, new lentiviral stocks were generated for 623 
selected ISGs and the inhibitory effect was measured through triplicate 624 
titrated challenges fixed at 48 h.p.i (BUNV EGFP) or 24 h.p.i (RVFV EGFP) 625 
(57).  The ISG-expressing Vero cells were selected and maintained in 626 
medium containing 10μg/ml puromycin. 627 
 628 
Virus infection and titration. For the infectious yield assays, cells were 629 
seeded in either 12-well or 6-well plates and were infected using a multiplicity 630 
of infection (MOI) of 0.1 to 0.001 (see figure legends). The infected cell culture 631 
supernatants were harvested after incubation for 48 or 72 h. Virus titres were 632 
determined by plaque assay. Briefly, cell monolayers were infected with the 633 
serially diluted virus and incubated for 1h at 37 ℃ and then were covered with 634 
a 0.6% Avicel (FMC Biopolymer) -MEM overlay medium supplemented with 635 
2% NBS or FBS. After incubation for 3 to 11 days depending on the 636 
respective virus, cells were fixed with 4% formaldehyde/PBS and stained with 637 
0.5% (w/v) methyl violet to visualize the plaques. Virus titres were calculated 638 
and presented as PFU/ml. For PUUV only, the foci were visualized using an 639 
immunofocus assay as described previously (4). 640 
 641 
Infectious VLP Assays. The VLP assay was performed as described 642 
previously with minor modifications (71). In brief, BSRT7/5 cells grown in 6-643 
well plates were transfected with plasmids pTM1-BUNVN (0.2 μg), pTM1-644 
BUNL (0.3μg), pTM1-BUNM (0.2 μg) and one of the following BUNV derived 645 
minigenomes (0.4μg) pT7riboBUNLRen(-), pT7riboBUNMRen(-), or 646 
pT7riboBUNSRen(-), using transfection reagent TransIT-LT1 (MirusTM). At 24 647 
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h posttransfection, supernatant was harvested and clarified at 4000 rpm for 3 648 
min. The VLP-containing supernatant was serially diluted and used to infect 649 
Vero-ISG cells seeded in 96-well plates. Renilla luciferase activity was 650 
measured after a further 24h incubation by using a Dual-Luciferase Assay kit 651 
(Promega) according to the manufacturer's instruction. 652 
 653 
Western blotting. Cell lysates were prepared by the addition of SDS sample 654 
buffer (20% glycerol, 100 mM Tris-HCl [pH 6.8], 4% SDS, 200 mM 655 
dithiothreitol [DTT], 0.2% bromophenol blue). Proteins were then separated 656 
on NuPage 4-12% Bis-Tris gradient polyacrylamide gels (Nu-PAGE; Life 657 
Technologies) and wet-transferred to a nitrocellulose blotting membrane (GE 658 
Healthcare). The membrane was blocked in SEA BLOCK blocking buffer 659 
(Thermo Scientific, Catalog:37527) for 2h at room temperature and then 660 
probed with the rabbit anti-human ISG20 polyclonal antibody (Thermofisher 661 
Scientific, Catalog:PA5-30073) and mouse anti-tubulin monoclonal antibody 662 
(Sigma, Catalog:T5168) at room temperature for 2h. After washing with PBS-663 
TWEEN-20, the membrane was subsequently probed with the fluorescent 664 
secondary antibodies, goat anti-rabbit antibody (IRDye® 680RD labelled, 665 
ThermoScientific) and goat anti-mouse (IRDye® 800CW labelled, LI-COR 666 
Biosciences). The blots were scanned using a quantitative Li-Cor Odyssey 667 
Scanner.  The blotting in figure 3A was performed as described previously  (4) 668 
using antibodies raised against EHD4  (Ab153892), SCO2 (ab169042) and 669 
LGALS9 (ab153673) from abcam in addition to antibodies against HK II (sc-670 
130358), IFTM3 (sc-100768), IRF1 (Sc-135952), NOS2A (Hs sc-7271) and 671 
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RHOB (sc-8048) from Santa Cruz.  We were unable to establish a western 672 
blot assay for NOS2A or RHOB. 673 
 674 
 675 
Virus in vitro evolution. Vero-ISG20 cells in T25 flasks were initially infected 676 
with the parental BUNV at MOI 0.01. After 48h, the supernatant (passage 1) 677 
was used to infect a fresh batch of Vero-ISG20 cells. Subsequent passages 678 
were performed up to passage 40 using MOI ~0.01. A parallel passage series 679 
was completed using Vero-EMPTY cells (transduced with an ‘empty’ 680 
SCRPSY vector) as a substrate, also for 40 passages to monitor adaptation to 681 
transduced Vero cells. The supernatants were collected and stored at -80°C 682 
and virus titre was determined by plaque assay on Vero cells. 683 
 684 
Virus genome sequencing and 3'-RACE. To determine the genomic 685 
sequences of the parental BUNV and ISG20-resistent BUNV, Vero and Vero-686 
ISG20 cells were infected with parental BUNV and ISG20-resistant BUNV at 687 
MOI 0.1, respectively. Cells were lysed in TRIzol (Invitrogen) at 24 h.p.i, and 688 
total cellular RNA was extracted in accordance with the manufacturer’s 689 
instructions. The viral RNA was subsequently amplified by RT-PCR using 690 
GoScript reverse transcriptase (Promega) and Q5 high fidelity DNA 691 
polymerase (New England BioLabs), and the sequence was determined by 692 
direct sequencing of the PCR products (Eurofins Genomics). 693 
 The sequence of the termini of the viral segments was determined by 694 
3'-RACE (3'-rapid amplification of cDNA ends). Extracted RNA was 695 
polyadenylated using a poly(A) tailing kit (Ambion) to generate 3'-poly(A)-696 
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tailed genomic and antigenomic RNAs. cDNA was prepared using oligo(dT). 697 
The 3' termini were then PCR amplified using oligo(dT) (Ambion) and a 698 
sequence specific internal primer. The sequence of the 5' UTR of the genomic 699 
RNA was determined by sequencing the 3' UTR of the antigenomic RNA (as 700 
above). The amplified fragments were gel purified and the sequence was 701 
determined by Eurofins Genomics. 702 
 703 
BUNV S segment qRT-PCR. Vero-EMPTY, Vero-ISG20 and Vero-ISG20D94G 704 
were infected with BUNV at MOI 10. At 0, 2, 4 and 6 h.p.i, cells were lysed in 705 
TRIzol and total cellular RNA was extracted as described above. Following 706 
quantification using a NanoDrop 2000 (Thermo Scientific), RNAs were 707 
reverse transcribed into cDNA using strand-specific tagged RT primers and 708 
SuperScript III first-strand synthesis system. RNA standards generated from 709 
In vitro transcribed viral genomic RNA (gRNA), anti-genomic RNA (cRNA) and 710 
mRNA were used as quantification standards. Quantitative PCR was 711 
performed using 'Brilliant III Ultra-Fast QPCR Master Mix' from Agilent 712 
Technologies using the Stratagene Mx3005P platform from Agilent 713 
Technologies. Each qPCR reaction was performed in a 20µl scale (6.2µl 714 
dH2O, 10µl 2x MasterMix, 0.5 µl Forward oligo (10µM), 0.5µl Reverse oligo 715 
(10µM), 0.5µl Probe (5 µM), 0.3µl ROX (1:500 dilution) and 2µl cDNA 716 
template). The qPCR cycling parameters were 95℃ for 3 minutes, followed by 717 
40 cycles of 95 ℃ for 10s, 60 ℃ for 22s. Each reaction was performed in 718 













Virus rescue using reverse genetics. Virus rescues were performed as 721 
described previously with minor modifications (72). In brief, subconfluent 722 
BSRT7/5 cells were transfected with a mixture of plasmids comprising 1.0 g 723 
each of either wild type or mutant (specified in the relevant figure legends) 724 
pTVT7 BUNL(+), pTVT7 BUNM(+) and pTVT7 BUNS(+) and 9 l of 725 
transfection reagent TransIT-LT1 (Mirus Bio LLC) in 0.7 mL of Opti-MEM 726 
medium (Life Technologies). After 4h transfection, 4 mL of growth medium 727 
was added and incubation continued for 4 days or until the cytopathic effect 728 
(CPE) was evident. Supernatant was harvested and stored at -80°C. 729 
 730 
Biological interferon assay. The biological assay for IFN production was 731 
performed as described previously (73). Briefly, ‘IFN-competent’ HeLa cells 732 
were infected with different BUNV mutants (MOI 3) and incubated at 37°C for 733 
24 h. Supernatant was clarified by brief centrifugation and inactivated by UV 734 
irradiation.  The UV-inactivated supernatant was two-fold-serially diluted and 735 
used to treat ‘IFN-incompetent’ A549-Npro cells (expressing the bovine viral 736 
diarrhea virus NPro protein). Cells were infected with encephalomyocarditis 737 
virus (EMCV) at MOI 0.01 and fixed (8% formaldehyde) and stained with 738 
Methyl violet staining solution (5% m/v). 739 
 740 
Figure legends 741 
FIG 1 BUNV-eGFP completes a single round of infection in MT4 cells. (A) 742 
A typical confocal microscopy field of MT4 cells infected with BUNV-eGFP and 743 
stained with DAPI. (B) Pseudocolored flow cytometry dot plots of MT4 cells 744 
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infected and uninfected with BUNV-eGFP. (C) A growth curve of BUNV-eGFP 745 
on MT4 cells. MT4 cells were infected with BUNV-GFP at MOI 5 (determined 746 
using Vero cells). (D) Growth kinetics of wtBUNV and BUNV-eGFP in MT4 747 
cells. MT4 cells were infected with the same MOI of wtBUNV or BUNV-eGFP, 748 
respectively. At different time points the supernatant was harvested and the 749 
infectious titer was determined using Vero cells. (E) Plaques of wtBUNV and 750 
BUNV-eGFP (on Vero cells) produced by MT4 cells. 751 
 752 
FIG 2 ISG expression screening reveals novel candidate genes with anti-753 
BUNV activity. (A) Schematic representation of H. sapiens and M. mulatta 754 
ISG libraries. The libraries are in a 96-well plate format with one ISG per well. 755 
(B) Simplified schematic of the pSCRPSY-DEST lentiviral vector (dotted line: 756 
mRNA splicing). (C) Schematic representation of the ISG screen. MT4 cells 757 
were transduced with the ISGs libraries. After 48h, cells were subsequently 758 
challenged with BUNV-eGFP and the infectivity of BUNV-eGFP in ISG-759 
expressing MT4 cells was quantified by flow cytometry 48 h.p.i. (D) Results of 760 
screening. Each dot represents one ISG. Infectivity measured from each ISG-761 
expressing well has been normalized to the average of the screen, which is 762 
indicated as 100. (E) Confirmatory assays for the selected top 20 H. sapiens 763 
and M. mulatta candidate inhibitory ISGs. New lentiviral stocks independent 764 
from the primary screen were made and used to transduce MT4 cells. BUNV-765 
eGFP infection was performed as in the primary screen. Infectivity presented 766 













FIG 3 The antibunyaviral activity of candidate ISGs on a panel of 769 
divergent bunyaviruses. (A) ISG expression in ten Vero-ISG expressing cell 770 
lines in addition to ‘empty vector’ and naïve Vero cell controls was assessed 771 
using western blotting (assays were not established for NOS2A and RHOB) 772 
(B) As in A, lentiviral vector-encoded TagRFP expression was monitored by 773 
flow cytometry. (C) Infectious virus yield from ten Vero-ISG expressing cell 774 
lines. Cells were infected with 15 wild type bunyaviruses representing 4 775 
families. Supernatant was collected and virus yield was determined on Vero or 776 
BHK-21. MOI and time point of supernatant harvest were: BUNV, CVV, KRIV, 777 
SBV, DUGV, RVFV and SFTSV MOI 0.001, 72 h.p.i; OROV MOI 0.001, 48 778 
h.p.i; ANAV, BMAV, BORV, CAPV and TCMV MOI 0.01, 48 h.p.i; PUUV MOI 779 
0.1, 48 h.p.i; HRTV MOI 0.01, 72h.p.i. (EMPTY: Vero cells transduced with 780 
EMPTY SCRPSY lentiviral stocks). (D) Heat map analysis (generated by 781 
Graphpad Prism 7) of the effect of 10 ISGs on the yield of 15 bunyaviruses. 782 
(Hs: H. sapiens; Mm: M. mulatta). (E) Summary of human ISG20 antiviral 783 
effect on 15 bunyaviruses.  784 
 785 
FIG 4 A single point mutation in the active site (ISG20
D94G
) abolishes the 786 
antibunyaviral activity of ISG20. (A) Schematic representation of the three 787 
exonuclease active motifs (Exo I, II & III) of ISG20 (shown in grey boxes). The 788 
conserved amino acid residues (from the DEDDh family) are highlighted in 789 
green. The Asp 94 (shown in green) of wild type ISG20 was substituted with 790 
Gly to generate the catalytically inactive mutant ISG20
D94G
. Four amino acids 791 
differences between human and macaque ISG20 are highlighted with yellow 792 
boxes (shown in red letters). (B) Plaque phenotypes of wtBUNV on Vero-793 
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EMPTY and Vero-ISG20/ ISG20
D94G
. (C) Quantification of plaque area (mm
2
) 794 
and (D) virus titers of BUNV on Vero-EMPTY and Vero-ISG20/ ISG20
D94G 
795 
cells. (E) Western blotting of ISG20/ ISG20
D94G
 protein expression. Cell 796 
lysates were probed with anti-ISG20 polyclonal antibody. Tubulin served as a 797 
sample loading control. (F) As in E, using ‘bulk populations’ of Vero cells 798 
expressing human and macaque ISG20.  (G) Titration curves of the ‘bulk 799 
populations’ in E infected with BUNV-EGFP (46) or single cycle RVFV (57) 800 
mean and SD of triplicate titrations is shown. 801 
 802 
FIG 5 Gene expression from all BUNV genome segments is inhibited by 803 
ISG20. (A) Serially diluted single segment VLPs were used to infect Vero-804 
EMPTY, Vero-ISG20 and Vero-ISG20D94G cells. At 24 h.p.i, cells were lysed 805 
for testing of Renilla luciferase activity (Mean ± SD, n=3) and luciferase 806 
activity at the indicated VLP inoculum (l) is shown. (B) Antiviral effect of 807 
interferon on single segment VLPs. Unmodified naïve Vero cells were treated 808 
or mock treated with 1000U/ml universal interferon for 24h. The cells were 809 
subsequently infected with 200μl of serially diluted VLPs. After 24h, cells were 810 
lysed for testing of renilla luciferase activity (Mean ± SD, n = 3). (C) RT-qPCR 811 
strategies for detection of BUNV S segment RNAs. Strand-specific tagged 812 
reverse transcription primers were used for generating cDNAs of S segment 813 
genomic RNA (gRNA), anti-genomic RNA (cRNA) and messenger RNA 814 
(mRNA), which were subsequently analysed by qPCR. The mRNA qPCR 815 
primers would amplify all positive sense viral RNAs. Using cRNA specific 816 
qPCR primers, mRNA was quantified by subtracting cRNA abundance from 817 
all positive sense viral RNAs. (Arrows: qPCR primers; Red bar:  Taqman 818 
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probe sequence; Yellow ball: FAM fluorescent dye; Black ball: Blackhole 819 
quencher 1). (D) Validation of primer specificity. 5x106 copies of gRNA, cRNA 820 
or mRNA (in vitro transcribed standards) were reverse transcribed using 821 
gRNA, cRNA and mRNA RT primers, respectively. cDNA was then quantified 822 
using strand-specific qPCR primers. (E) Vero-EMPTY/ISG20/ISG20D94G were 823 
infected with wtBUNV at MOI 10. At 0, 2, 4 and 6 h.p.i, cells were lysed with 824 
TRIzol and total cellular RNA was extracted for RT-qPCR analysis (Mean ± 825 
SD, n=3) 826 
 827 
FIG 6 Generation of an ISG20-resistant BUNV and endogenous ISG20 828 
possesses antibunyaviral activity. (A) Plaque phenotype (on Vero and 829 
Vero-ISG20 cells) and (B) fold inhibition of the parental virus, P20 and P40 830 
ISG20 resistant virus by ISG20 (fold reduction in PFU/ml comparing naïve 831 
and Vero-ISG20). (C) Comparison of growth curves of the parental virus and 832 
P40 virus on Vero-ISG20 and naïve Vero cells. Cells were infected at MOI 833 
0.01 (Mean ± SD, n=3). (D) Infectious yields (36 h postinfection with MOI 834 
0.01) of wild type (wt) BUNV and reassortant mutants (mutant segments 835 
denoted with a prime) from Vero-ISG20 or Vero-D94G cells (Mean ± range, 836 
n=2). (E) Biological IFN assays assessing the ability of supernatants from 837 
HeLa cells infected with the indicated viruses to inhibit the replication of 838 
EMCV in A549 Npro cells. (F) Western blot analysis of basal and inducible 839 
expression in naïve HeLa cells, HeLa-shGFP cells and HeLa-shISG20 cells. 840 
Basal expression or 500U/ml Universal interferon induced ISG20 expression 841 
was stably detected in naïve HeLa cells and HeLa-shGFP cells, whereas both 842 
basal and inducible ISG20 expression was undetectable in HeLa-shISG20 843 
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cells. (G) Growth curves of parental BUNV, P40 Vero-EMPTY passaged 844 
BUNV and P40 ISG20 resistant BUNV on HeLa cells MOI=0.01 (Mean ± SD, 845 
n=3). (H) Growth curves of the parental BUNV and P40 ISG20 resistant 846 
BUNV on HeLa-shGFP (control) and HeLa-shISG20 cells. 847 
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  1103 
Rank Gene symbol Gene Name 
ISGs/SCRPY EMPTY -
fold inhibition 
1 IRF1 interferon regulatory factor 1 13.94188652 
2 IFITM3 interferon induced transmembrane protein 3 10.81898208 
3 ISG20 interferon stimulated exonuclease gene 20kDa 10.51226219 
4 EHD4 EH-domain containing protein 4 8.337769295 
5 NOS2A nitric oxide synthase 2a 8.142114105 
6 INDO/IDO indoleamine-pyrrole 2,3 dioxygenase 7.431693179 
7 SCO2 SCO cytochrome oxidase deficient homolog 2 6.682186081 
8 HK2 hexokinase 2 6.600853655 
9 BCL3 B-cell CLL/lymphoma 3  5.560601225 
10 IRF7 interferon regulatory factor 7 4.996490044 
11 C5ORF39 annexin A2 receptor 4.532151199 
12 NUP50 nucleoporin 50kDa 4.502720506 
13 OAS2 2'-5'-oligoadenylate synthetase 2 3.857183543 
14 TLK2 tousled-like kinase 2 3.560273013 
15 PXK PX Domain Containing Serine/Threonine Kinase Like  3.333094361 
16 MX1 myxovirus (influenza virus) resistance 1 3.019964468 
17 IFIT5 interferon-induced protein with tetratricopeptide repeats 5 2.697749553 
18 LGALS9 galectin 9, beta-galactoside-binding protein 2.222739332 
19 CCNA1 cyclin A1  2.017553608 
20 TNFRSF10A tumour necrosis factor receptor superfamily, member 10a  1.181220011 
 o
n









Table 2 Confirmatory assays for M. mulatta ISGs 1104 
  1105 
Rank Gene symbol Gene Name 
ISGs/SCRPY EMPTY- 
fold inhibition 
1 IFNβ1 interferon beta 1 25.68764253 
2 ISG20 interferon stimulated exonuclease gene 20kDa 16.51376275 
3 INDO/IDO indoleamine-pyrrole 2,3 dioxygenase 11.89015349 
4 LGALS9 galectin 9, beta-galactoside-binding protein 6.99430233 
5 PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 5.758834317 
6 RHOB ras homolog family member B  5.195047578 
7 BCL3 B-cell CLL/lymphoma 3  4.754072894 
8 TLK2 tousled-like kinase 2 4.709891813 
9 ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3, isotype 4.611043388 
10 IRF7 interferon regulatory factor 7 4.174521863 
11 CCNA1 cyclin A1  3.389544757 
12 IFITM3 interferon induced transmembrane protein 3 3.301078884 
13 HK2 hexokinase 2 3.060345699 
14 PXK PX Domain Containing Serine/Threonine Kinase Like  2.855499432 
15 IRF1iso3 interferon regulatory factor 1, isotype 2.770775682 
16 IFITM3 interferon induced transmembrane protein 3 2.64956607 
17 IFITM2 interferon induced transmembrane protein 2 2.495300874 
18 IFIT5 interferon-induced protein with tetratricopeptide repeats 5 1.868064022 
19 ZNF385B zinc finger protein 385B 1.802174105 
20 TNFRSF10A tumour necrosis factor receptor superfamily, member 10a  1.363085906 
 o
n










Table 3 – Nucleotide and amino acid changes of BUNV passaged on VERO-ISG20 cells* 1107 
 1108 
Segment 
Nucleotide mutations Amino acid 
mutations 
Note 
Position P0 P20 P40 
L 
3257 nt G G A Synonymous  
5267 nt A A G I1740M L protein 
6538 nt A A/G# G E2163A L protein 
       
 518 nt T T/A# T Synonymous  
 1371 nt G G/A# G V439I NSm 
M 3568 nt A G& G& N1171S Gc Protein 
 4388 nt A A/G# G none 
cRNA 3’ 
UTR 
       
 112 nt C C/T# T Synonymous N protein 
S     S3L NSs protein 
       
 330 nt A C C N82T N protein 
     T76P NSs protein 
*The following differences were observed in the P0 virus relative to GenBank 1109 
L segment (NC_001925.1): T5501C (silent), 6809nt C Insertion in 5’ UTR. 1110 
M segment (NC_001926.1): G415A (R120K), A417G (K121E), G1423A (R456K), A1941G (S629G), C2638T 1111 
(P861L), G2829A (E925K), T3359C (silent), G3568A (S1171N), A4008G (R1381G) and G4317A (A1421T). 1112 
S segment (NC_001927.1): N/A 1113 
 # polymorphism 1114 






Table 4 – Nucleotide and amino acid changes of BUNV passaged on VERO-EMPTY cells* 1121 
Segment 
Nucleotide mutations Amino acid 
mutations 
Note 
Position P0 P20 P40 
L 
3299 nt A A T Synonymous  
3622 nt A A A/G# E1191G L protein 
       
 518 nt T T/A# T Synonymous  
 1371 nt G G/A# G V439I NSm 
M 2500 nt C T T P815L Gc protein 
 4240 nt T T/A# A I1395N Gc protein 
       
 84 nt T T C none 3’ UTR 
S 118 nt T T C Synonymous N protein 
     L5P NSs protein 
       
 165 nt A G G K27R N protein 
     S21G NSs protein 
*The following differences were observed in the P0 virus relative to GenBank 1122 
L segment (NC_001925.1): T5501C (silent), 6809nt C Insertion in 5’ UTR. 1123 
M segment (NC_001926.1): G415A (R120K), A417G (K121E), G1423A (R456K), A1941G (S629G), C2638T 1124 
(P861L), G2829A (E925K), T3359C (silent), G3568A (S1171N), A4008G (R1381G) and G4317A (A1421T). 1125 
S segment (NC_001927.1): N/A 1126 
 # polymorphism 1127 
 1128 
  1129 
 o
n









Table 5 Primers used in BUNV S segment RT-qPCR reactions (S segment 1130 
Genbank accession number NC_001927.1) 1131 
 1132 
Note: Underlined italic sequences are the non-viral tags. 1133 
 1134 
 Oligo sequences  
5’→3’ 






      
 
      
 






      
 
    903-924 









gRNA:  Forward: CGACATCATGAAATTCCAA 
             Probe: [FAM] ATCCAACAGAAGGTCATTAAAGGCTC [BHQ1] 
             Reverse:  GGCCGTCATGGTGGCGAAT 
     
    849-867 
    881-906 
 
             
qPCR 
cRNA:  Forward: ACAAAATAACAGCTGCTTGG 
             Probe: [FAM] TTTAGCCCGCTGTCTTTCTGTCCC [BHQ1] 
             Reverse:  GCTAGCTTCAGCTAGGCATC 
    856-875 
    887-910 
 
 mRNA:  Forward: CAGTTGTCTCTAGCTTAGGTTGG               
              Probe: [FAM] TCCCTGGCAGCTGCACTAACATT [BHQ1] 
              Reverse:  CCAGATCGTTCGAGTCGT 
    702-724 
    734-756 
 o
n
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